Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

1,206 Followers
See the Price Targets and Ratings of:
See bloggers sentiment and opinion on ARWR
>

ARWR Analyst Ratings

Strong Buy
8Ratings
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Arrowhead
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARWR Stock 12 Months Forecast

Average Price Target

$58.43
▲(123.02% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $58.43 with a high forecast of $90.00 and a low forecast of $33.00. The average price target represents a 123.02% change from the last price of $26.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Proxima_Nova_regular","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","58":"$58","91":"$91","41.5":"$41.5","74.5":"$74.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.43,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$58.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,41.5,58,74.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Sep<br/>2023","25":"Sep<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.96,32.73230769230769,37.504615384615384,42.27692307692308,47.049230769230775,51.821538461538466,56.59384615384616,61.36615384615385,66.13846153846154,70.91076923076923,75.68307692307692,80.45538461538462,85.22769230769231,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.96,30.303846153846155,32.64769230769231,34.99153846153846,37.33538461538461,39.67923076923077,42.02307692307692,44.36692307692307,46.71076923076923,49.05461538461539,51.39846153846154,53.74230769230769,56.08615384615385,{"y":58.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.96,28.34769230769231,28.735384615384618,29.123076923076923,29.51076923076923,29.89846153846154,30.286153846153848,30.673846153846153,31.06153846153846,31.44923076923077,31.836923076923078,32.22461538461538,32.612307692307695,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.93,"date":1663891200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.62,"date":1665100800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.96,"date":1667520000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.93,"date":1669939200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.38,"date":1672963200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.74,"date":1675382400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.35,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.17,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.38,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.05,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.65,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.96,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$90.00Average Price Target$58.43Lowest Price Target$33.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners
Hold
Reiterated
SVB Securities Sticks to Its Hold Rating for Arrowhead Pharmaceuticals (ARWR)
Morgan Stanley
$40.00
Hold
52.67%
Upside
Reiterated
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Sarepta Therapeutics (NASDAQ: SRPT) and LivaNova (NASDAQ: LIVN)
SMBC Nikko
$80.00
Buy
205.34%
Upside
Initiated
SMBC Nikko Securities starts Arrowhead Pharma (ARWR) at OutperformSMBC Nikko Securities analyst David Hoang initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Outperform rating and a price target of $80.00.
Jefferies
$75.00
Buy
186.26%
Upside
Reiterated
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies
Bernstein Analyst forecast on ARWR
Unknown Analyst
Not Ranked
Bernstein
$27.00
Hold
3.05%
Upside
Reiterated
We are most interested to hear the company's plans in adipose tissue; if anything at R&D day is going to be a positive surprise for the stock, this will likely be it. At the prior earnings call, CEO Chris Anzalone stated that they had achieved over 90% silencing in NHPs with 6+ months duration. Our questions are mostly around delivery, localization, and safety. In pulmonary, we will see additional healthy volunteer data in ARO-RAGE including the highest dose (SAD but not MAD), and we will see healthy volunteer data for the first time in ARO-MUC5AC. As a reminder, Arrowhead presented impressive knockdown data for ARO-RAGE at the end of April (80% mean-max serum sRAGE reduction for those receiving 2 doses, Exhibit 3). Our expectations in MUC5AC are slightly lower. T olerability in asthma patients is an open question for us, but we won't see that until later in the year.

Best Analysts Covering Arrowhead Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy ARWR and Sell After:
1 Month
Madhu KumarGoldman Sachs
Success Rate
9/15 ratings generated profit
60%
Average Return
+2.85%
reiterated a buy rating 4 months ago
Copying Madhu Kumar's trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +2.85% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Keay NakaeChardan Capital
Success Rate
19/33 ratings generated profit
58%
Average Return
+12.26%
reiterated a buy rating 16 days ago
Copying Keay Nakae's trades and holding each position for 3 Months would result in 57.58% of your transactions generating a profit, with an average return of +12.26% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Keay NakaeChardan Capital
Success Rate
18/33 ratings generated profit
55%
Average Return
+41.36%
reiterated a buy rating 16 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +41.36% per trade.
2 Years
Keay NakaeChardan Capital
Success Rate
13/33 ratings generated profit
39%
Average Return
+70.50%
reiterated a buy rating 16 days ago
Copying Keay Nakae's trades and holding each position for 2 Years would result in 39.39% of your transactions generating a profit, with an average return of +70.50% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ARWR Financial Forecast

ARWR Earnings Forecast

Next quarter’s earnings estimate for ARWR is -$0.61 with a range of -$0.99 to $0.75. The previous quarter’s EPS was -$0.96. ARWR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.62% of the time in the same period. In the last calendar year ARWR has Underperformed its overall industry.
Next quarter’s earnings estimate for ARWR is -$0.61 with a range of -$0.99 to $0.75. The previous quarter’s EPS was -$0.96. ARWR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.62% of the time in the same period. In the last calendar year ARWR has Underperformed its overall industry.

ARWR Sales Forecast

Next quarter’s sales forecast for ARWR is $46.97M with a range of $4.00M to $203.90M. The previous quarter’s sales results were $15.82M. ARWR beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 44.67% of the time in the same period. In the last calendar year ARWR has Underperformed its overall industry.
Next quarter’s sales forecast for ARWR is $46.97M with a range of $4.00M to $203.90M. The previous quarter’s sales results were $15.82M. ARWR beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 44.67% of the time in the same period. In the last calendar year ARWR has Underperformed its overall industry.

ARWR Analyst Recommendation Trends

In the current month, ARWR has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ARWR average analyst price target in the past 3 months is $58.43
In the current month, ARWR has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ARWR average analyst price target in the past 3 months is $58.43

ARWR Stock Forecast FAQ

What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is $58.43.
    What is ARWR’s upside potential, based on the analysts’ average price target?
    Arrowhead Pharmaceuticals has 123.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARWR a Buy, Sell or Hold?
          Arrowhead Pharmaceuticals has a conensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Arrowhead Pharmaceuticals’s price target?
            The average price target for Arrowhead Pharmaceuticals is $58.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $90.00 ,the lowest forecast is $33.00. The average price target represents 123.02% Increase from the current price of $26.2.
              What do analysts say about Arrowhead Pharmaceuticals?
              Arrowhead Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of ARWR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis